Department of Ophthalmology, Qilu Hospital of Shandong University, Jinan, 250012, P.R. China.
Department of Ophthalmology, Shandong Provincial ENT Hospital affiliated to Shandong University, Jinan, 250023, P.R. China.
J Int Med Res. 2020 Apr;48(4):300060519893176. doi: 10.1177/0300060519893176.
This study assessed the efficacy of conbercept for patients with non-proliferative diabetic retinopathy (NPDR).
In this retrospective clinical study, 54 patients with NPDR (54 eyes) were treated with intravitreal injection of conbercept using a 3+ pro re nata regimen and followed up for 12 months. Best corrected visual acuity (BCVA), central foveal thickness (CFT), area of hard exudate (HE), and number of microaneurysms (MAs) were used as indicators of therapeutic effects. Systemic adverse reactions were recorded to assess safety.
During the 12-month follow-up period, the mean number of injections was 6.12 ± 1.89 on demand. From baseline to the 12-month follow-up, the BCVA of patients with NPDR increased from 0.71 ± 0.20 logMAR to 0.43 ± 0.16 logMAR, CFT decreased from 424.26 ± 64.89 μm to 269.27 ± 44.79 μm, and the number of MAs declined from 79.53 ± 27.18 to 33.34 ± 16.53. Moreover, the area of HE was significantly reduced after 9 months of treatment. There were no serious systemic adverse events during the follow-up.
Intravitreal injection of conbercept has a stable and robust effect on patients with NPDR over a 12-month follow-up period. Thus, conbercept is an effective and feasible treatment for NPDR.
本研究评估了康柏西普治疗非增生性糖尿病视网膜病变（NPDR）的疗效。
本回顾性临床研究纳入了 54 例 NPDR 患者（54 只眼），给予康柏西普玻璃体腔内注射，采用 3+按需治疗方案，并随访 12 个月。最佳矫正视力（BCVA）、中心视网膜厚度（CFT）、硬性渗出（HE）面积和微动脉瘤（MA）数量用作疗效指标。记录全身不良反应以评估安全性。
在 12 个月的随访期间，按需注射的平均次数为 6.12±1.89 次。从基线到 12 个月随访时，NPDR 患者的 BCVA 从 0.71±0.20 logMAR 提高到 0.43±0.16 logMAR，CFT 从 424.26±64.89μm 降低到 269.27±44.79μm，MA 数量从 79.53±27.18 个减少到 33.34±16.53 个。此外，治疗 9 个月后 HE 面积显著减少。随访期间无严重全身不良事件。
康柏西普玻璃体腔内注射在 12 个月的随访期内对 NPDR 患者具有稳定而强大的疗效。因此，康柏西普是 NPDR 的一种有效且可行的治疗方法。
